BRPI0511139B8 - compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos - Google Patents

compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos

Info

Publication number
BRPI0511139B8
BRPI0511139B8 BRPI0511139A BRPI0511139A BRPI0511139B8 BR PI0511139 B8 BRPI0511139 B8 BR PI0511139B8 BR PI0511139 A BRPI0511139 A BR PI0511139A BR PI0511139 A BRPI0511139 A BR PI0511139A BR PI0511139 B8 BRPI0511139 B8 BR PI0511139B8
Authority
BR
Brazil
Prior art keywords
compounds
aurora kinase
pharmaceutical composition
same
composition containing
Prior art date
Application number
BRPI0511139A
Other languages
English (en)
Portuguese (pt)
Inventor
F Claiborne Christopher
S Weatherhead Gabriel
J Payne Lloyd
j boyce Richard
G Stroud Stephen
Travers Stuart
B Sells Todd
J Vos Tricia
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of BRPI0511139A publication Critical patent/BRPI0511139A/pt
Publication of BRPI0511139B1 publication Critical patent/BRPI0511139B1/pt
Publication of BRPI0511139B8 publication Critical patent/BRPI0511139B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Small-Scale Networks (AREA)
BRPI0511139A 2004-05-14 2005-05-12 compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos BRPI0511139B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57165304P 2004-05-14 2004-05-14
US60/571,653 2004-05-14
US61722104P 2004-10-08 2004-10-08
US60/617,221 2004-10-08
PCT/US2005/016445 WO2005111039A2 (en) 2004-05-14 2005-05-12 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase

Publications (3)

Publication Number Publication Date
BRPI0511139A BRPI0511139A (pt) 2007-11-27
BRPI0511139B1 BRPI0511139B1 (pt) 2019-05-21
BRPI0511139B8 true BRPI0511139B8 (pt) 2021-05-25

Family

ID=35262144

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511139A BRPI0511139B8 (pt) 2004-05-14 2005-05-12 compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos

Country Status (25)

Country Link
US (9) US7572784B2 (enExample)
EP (4) EP2261226B1 (enExample)
JP (4) JP4467616B2 (enExample)
KR (3) KR101792651B1 (enExample)
CN (1) CN104193750B (enExample)
AR (1) AR049277A1 (enExample)
AT (1) ATE381566T1 (enExample)
AU (1) AU2005243175B2 (enExample)
BR (1) BRPI0511139B8 (enExample)
CA (1) CA2565411C (enExample)
CY (2) CY1108092T1 (enExample)
DE (1) DE602005003951T4 (enExample)
DK (1) DK1771450T5 (enExample)
EA (1) EA012112B1 (enExample)
ES (3) ES2391577T3 (enExample)
HR (2) HRP20080120T5 (enExample)
IL (1) IL179063A (enExample)
MX (1) MXPA06013042A (enExample)
MY (1) MY139355A (enExample)
NZ (1) NZ551370A (enExample)
PL (1) PL1771450T3 (enExample)
PT (2) PT1771450E (enExample)
RS (2) RS52436B (enExample)
TW (1) TWI338688B (enExample)
WO (1) WO2005111039A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101792651B1 (ko) * 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
EP1799684B1 (en) 2004-10-04 2014-12-03 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2006046734A2 (ja) * 2004-10-29 2006-05-04 Banyu Pharma Co Ltd オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
CN101166732B (zh) 2005-04-28 2013-04-17 田边三菱制药株式会社 氰基吡啶衍生物及其作为药物的应用
MX2007013257A (es) * 2005-05-05 2008-01-21 Chroma Therapeutics Ltd Conjugados de ester de alfa-aminoacido-farmaco hidrolizables por carboxilesterasa.
US8624027B2 (en) * 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
WO2007087246A2 (en) * 2006-01-24 2007-08-02 Merck & Co., Inc. Jak2 tyrosine kinase inhibition
WO2007108936A2 (en) * 2006-03-15 2007-09-27 Wyeth N-substituted-azacyclylamines as histamine-3 antagonists
WO2007107469A1 (en) * 2006-03-20 2007-09-27 F. Hoffmann-La Roche Ag Methods of inhibiting btk and syk protein kinases
CA2649913A1 (en) * 2006-05-19 2007-11-29 Wyeth N-benzoyl- and n-benzylpyrrolidin-3-ylamines as histamine-3 antagonists
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
AU2014280932B2 (en) * 2006-11-16 2016-10-06 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AU2012203952B2 (en) * 2006-11-16 2014-12-11 Millennium Pharmaceuticals, Inc. Compounds for inhibiting mitotic progression
AR066721A1 (es) * 2007-05-24 2009-09-09 Wyeth Corp Derivados de benzo[d]imidazol-1-il, composicion farmaceutica, proceso de preparacion y uso.
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
CA2693138A1 (en) * 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
KR20100067102A (ko) * 2007-09-04 2010-06-18 바이올리폭스 에이비 염증의 치료에 유용한 비스-방향족 화합물
US20090069300A1 (en) * 2007-09-12 2009-03-12 Wyeth Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
JP2009108036A (ja) * 2007-09-28 2009-05-21 Fujifilm Corp 新規アセチレン化合物、その製造方法、それを構成単位として含むポリマー、該化合物及び／又は該ポリマーを含む組成物、該組成物を硬化させてなる硬化物
ES2427892T3 (es) * 2008-02-29 2013-11-04 Chroma Therapeutics Limited Inhibidores de MAP quinasa p38
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
AU2009241469B2 (en) 2008-04-30 2015-05-07 National Health Research Institutes Fused bicyclic pyrimidine compounds as Aurora kinase inhibitors
US20110112193A1 (en) * 2008-05-14 2011-05-12 Peter Nilsson Bis-aryl compounds for use as medicaments
US7998952B2 (en) * 2008-12-05 2011-08-16 Millennium Pharmaceuticals, Inc. Thiolactams and uses thereof
CN102264368B (zh) 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
US20120035217A1 (en) 2009-03-12 2012-02-09 Biolipox Ab Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors
WO2010103297A2 (en) 2009-03-12 2010-09-16 Biolipox Ab Bis aromatic compounds for use as ltc4 synthase inhibitors
TW201035050A (en) 2009-03-12 2010-10-01 Biolipox Ab Bis aromatic compounds for use as LTC4 synthase inhibitors
CN102341371A (zh) 2009-03-12 2012-02-01 比奥里波克斯公司 用作ltc4合酶抑制剂的双芳族化合物
US8546377B2 (en) * 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8518933B2 (en) 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
WO2011103089A1 (en) 2010-02-19 2011-08-25 Millennium Pharmaceuticals, Inc. Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate
EP2545036A1 (en) 2010-03-12 2013-01-16 Biolipox AB Bis aromatic compounds for use as ltc4 synthase inhibitors
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2013142817A2 (en) 2012-03-23 2013-09-26 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
CN103804391A (zh) * 2012-11-01 2014-05-21 韩冰 一类治疗神经退行性疾病的化合物及其用途
EP2976086B1 (en) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
CN103408552B (zh) * 2013-07-25 2015-07-01 苏州明锐医药科技有限公司 阿立塞替的制备方法
US10335494B2 (en) 2013-12-06 2019-07-02 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-CD30 antibodies
EP3324976A4 (en) * 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
CN112062768B (zh) * 2020-07-20 2021-08-31 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 具有Aurora激酶降解活性的小分子及其制备方法和应用
AU2022415778A1 (en) * 2021-12-14 2024-07-04 Prazer Therapeutics Inc. Novel compound for degrading target protein or polypeptide by using polyubiquitination
WO2025087695A1 (en) 2023-10-23 2025-05-01 Ascend Advanced Therapies Ltd Method for producing recombinant adeno-associated virus particles

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022801A (en) 1974-06-03 1977-05-10 Ciba-Geigy Corporation Pyrazolobenzazepines
US3947585A (en) * 1974-06-03 1976-03-30 Ciba-Geigy Corporation Pyrazolobenzazepines
US4028381A (en) 1975-05-05 1977-06-07 Ciba-Geigy Corporation Pyrazolobenzazepines
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
ZA80492B (en) * 1979-02-07 1981-01-28 Hoffmann La Roche Benzazepine derivatives
KR840000061B1 (ko) 1979-02-07 1984-01-31 에프. 호프만-라 롯슈 앤드 캄파니 아크티엔 게젤샤프트 벤즈아제핀 유도체의 제조방법
SU1181547A3 (ru) 1979-02-07 1985-09-23 Ф.Хоффманн-Ля Рош Унд Ко,Аг (Фирма) Способ получени пиримидо-2-бензазепинов или их фармакологически совместимых кислотно-аддитивных солей (и его вариант)
US4547581A (en) 1979-02-07 1985-10-15 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines and intermediates in their preparation
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4318854A (en) 1979-02-07 1982-03-09 Hoffmann-La Roche Inc. Intermediates in the production of 2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
NL8102182A (nl) 1981-05-04 1982-12-01 Philips Nv Kleurenbeeldbuis.
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
EP0888350A1 (en) 1996-03-08 1999-01-07 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
AU5330698A (en) * 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
DK1026167T3 (da) 1997-09-29 2003-05-26 Meiji Seika Kaisha Tricykliske triazolobenzazepinderivater, fremgangsmåde til fremstilling af disse samt antiallergiske midler
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
HUP0401107A3 (en) 2001-08-09 2004-10-28 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles, their use process for their preparation and pharmaceutical compositions containing them
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
KR101792651B1 (ko) * 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
MX2007005857A (es) 2004-11-17 2007-10-10 Mikana Therapeutics Inc Inhibidores de cinasa.
EP1836188A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري

Also Published As

Publication number Publication date
PT1771450E (pt) 2008-03-31
DK1771450T3 (da) 2008-04-28
HK1114853A1 (en) 2008-11-14
US20160185782A1 (en) 2016-06-30
DE602005003951T4 (de) 2012-10-11
RS50568B (sr) 2010-05-07
HK1102500A1 (en) 2007-11-23
US20240083906A1 (en) 2024-03-14
BRPI0511139A (pt) 2007-11-27
IL179063A0 (en) 2007-03-08
US7572784B2 (en) 2009-08-11
US8399659B2 (en) 2013-03-19
PL1771450T3 (pl) 2008-05-30
DE602005003951D1 (de) 2008-01-31
NZ551370A (en) 2009-08-28
EP2261226B1 (en) 2015-04-01
US20090299060A1 (en) 2009-12-03
CA2565411C (en) 2010-04-20
US11014928B2 (en) 2021-05-25
JP2014114319A (ja) 2014-06-26
US20200247810A1 (en) 2020-08-06
JP4467616B2 (ja) 2010-05-26
RS50568B9 (sr) 2019-06-28
ES2540987T3 (es) 2015-07-15
HRP20080120T3 (hr) 2008-04-30
KR20070011606A (ko) 2007-01-24
KR101792651B1 (ko) 2017-11-20
HK1205102A1 (en) 2015-12-11
US9765078B2 (en) 2017-09-19
EP2261226A1 (en) 2010-12-15
CN104193750B (zh) 2018-04-27
US20180134716A1 (en) 2018-05-17
PT1905773E (pt) 2012-10-25
US10414770B2 (en) 2019-09-17
DE602005003951T2 (de) 2008-12-11
JP2008285484A (ja) 2008-11-27
RS52436B (sr) 2013-02-28
KR20120091275A (ko) 2012-08-17
MXPA06013042A (es) 2007-02-12
EP2719698B1 (en) 2016-10-05
HK1199254A1 (en) 2015-06-26
HRP20080120T5 (hr) 2012-07-31
EA200602100A1 (ru) 2007-04-27
RS50568B8 (sr) 2019-08-30
US20050256102A1 (en) 2005-11-17
WO2005111039A3 (en) 2006-04-20
CY1113192T1 (el) 2016-04-13
US20220041605A1 (en) 2022-02-10
JP2007537268A (ja) 2007-12-20
KR20130073993A (ko) 2013-07-03
CN104193750A (zh) 2014-12-10
TWI338688B (en) 2011-03-11
CY1108092T1 (el) 2014-02-12
HRP20120785T1 (hr) 2012-11-30
JP5148358B2 (ja) 2013-02-20
AU2005243175B2 (en) 2011-12-01
MY139355A (en) 2009-09-30
AU2005243175A1 (en) 2005-11-24
TW200604192A (en) 2006-02-01
IL179063A (en) 2016-05-31
ES2391577T3 (es) 2012-11-27
EP2719698A1 (en) 2014-04-16
JP5827708B2 (ja) 2015-12-02
JP2012006972A (ja) 2012-01-12
EA012112B1 (ru) 2009-08-28
CA2565411A1 (en) 2005-11-24
BRPI0511139B1 (pt) 2019-05-21
DK1771450T5 (da) 2012-01-09
AR049277A1 (es) 2006-07-12
EP1771450A2 (en) 2007-04-11
ATE381566T1 (de) 2008-01-15
EP1771450B9 (en) 2008-12-24
KR101748290B1 (ko) 2017-06-16
EP2746285A1 (en) 2014-06-25
WO2005111039A2 (en) 2005-11-24
ES2299080T3 (es) 2008-05-16
US9102678B2 (en) 2015-08-11
US20070185087A1 (en) 2007-08-09
EP2746285B1 (en) 2016-09-14
US20140046055A1 (en) 2014-02-13
EP1771450B1 (en) 2007-12-19

Similar Documents

Publication Publication Date Title
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
UA107783C2 (en) Isoindoline compounds for use in treating cancer
BRPI0718803B8 (pt) composto para inibir a progressão mitótica, composição farmacêutica e método in vitro para inibir a atividade de aurora cinase em uma célula
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
EA200970542A1 (ru) ИНГИБИТОРЫ ДЕЙСТВИЯ Akt
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
GEP20135785B (en) Pyrrolopyrimidine compounds as cdk inhibitors
EA200900571A1 (ru) Композиции chk1 ингибиторов
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
BR112012015714A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença neurodegenerativa, método para reduzir a concentração de p-ser-alfa-sinucleina em tecido cerebral, e, método para o tratamento de um câncer
TW200714604A (en) Substituted heterocycles and the uses thereof
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
BR112012008325A2 (pt) N-4 ( - ( ( 3- ( 2 - amino-4 pirimidinil) -2 -piridinil) oxi) fenil) -4- (4-metil-2-tienil) -1- ftalazinamina para uso no tratamento de câncer resistente a agente antimitótico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/05/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2879 DE 10-03-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.